C4 THERAPEUTICS INC's ticker is CCCC and the CUSIP is 12529R107. A total of 114 filers reported holding C4 THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $748,700 | -52.2% | 402,527 | -29.3% | 0.00% | -50.0% |
| Q2 2023 | $1,564,967 | +89.3% | 569,079 | +116.2% | 0.00% | +100.0% |
| Q1 2023 | $826,649 | +18.5% | 263,264 | +122.6% | 0.00% | 0.0% |
| Q4 2022 | $697,823 | -59.4% | 118,275 | -39.6% | 0.00% | -66.7% |
| Q3 2022 | $1,717,000 | -31.8% | 195,759 | -41.4% | 0.01% | -25.0% |
| Q2 2022 | $2,518,000 | -9.7% | 333,891 | +190.5% | 0.01% | 0.0% |
| Q1 2022 | $2,788,000 | +196.0% | 114,931 | +445.4% | 0.01% | +300.0% |
| Q3 2021 | $942,000 | +127.0% | 21,073 | +92.0% | 0.00% | +100.0% |
| Q2 2021 | $415,000 | – | 10,973 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 1,642,210 | $39,840,000 | 3.87% |
| Paradigm Biocapital Advisors LP | 499,496 | $12,118,000 | 3.20% |
| Cypress Point Wealth Management, LLC | 118,573 | $2,877,000 | 2.92% |
| COMMODORE CAPITAL LP | 481,094 | $11,671,000 | 2.61% |
| Nextech Invest Ltd. | 375,857 | $9,118,000 | 2.60% |
| RTW INVESTMENTS, LP | 4,531,982 | $109,946,000 | 2.28% |
| SPHERA FUNDS MANAGEMENT LTD. | 362,528 | $8,795,000 | 1.24% |
| Perceptive Advisors | 2,082,723 | $50,526,000 | 1.01% |
| CLOUGH CAPITAL PARTNERS L P | 356,181 | $8,641,000 | 0.66% |
| HighVista Strategies LLC | 34,760 | $843,000 | 0.54% |